DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing-Reference-Cited by-同舟云学术

DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing

Published:2015-08-10 Issue:1 Volume:6 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Nishina Kazutaka,Piao Wenying,Yoshida-Tanaka Kie,Sujino Yumiko,Nishina Tomoko,Yamamoto Tsuyoshi,Nitta Keiko,Yoshioka Kotaro,Kuwahara Hiroya,Yasuhara Hidenori,Baba Takeshi,Ono Fumiko,Miyata Kanjiro,Miyake Koichi,Seth Punit P.,Low Audrey,Yoshida Masayuki,Bennett C. Frank,Kataoka Kazunori,Mizusawa Hidehiro,Obika Satoshi,Yokota Takanori

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms8969.pdf

Reference62 articles.

1. Kole, R., Krainer, A. R. & Altman, S. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat. Rev. Drug Discov. 11, 125–140 (2012).

2. Jiang, K. Biotech comes to its 'antisenses' after hard-won drug approval. Nat. Med. 19, 252 (2013).

3. Miller, T. M. et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 12, 435–442 (2013).

4. Fitzgerald, K. et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383, 60–68 (2014).

5. Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819–829 (2013).

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA/RNA heteroduplex technology with cationic oligopeptide reduces class-related adverse effects of nucleic acid drugs;Molecular Therapy - Nucleic Acids;2024-09

2. RNase H-sensitive multifunctional ASO-based constructs as promising tools for the treatment of multifactorial complex pathologies;Bioorganic Chemistry;2024-09

3. Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice;Molecular Therapy - Methods & Clinical Development;2024-09

4. An anomalous 3’-terminal phosphorothioated mismatch bypass activity and its application as a binary molecular switch;2024-07-27

5. Therapeutic Targeting of PKM2 Ameliorates NASH Fibrosis Progression in A Macrophage-Specific and Liver-Specific Manner;Engineering;2024-05